| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025635610 |
| P356 | DOI | 10.1016/J.NURT.2007.05.006 |
| P932 | PMC publication ID | 1963417 |
| P698 | PubMed publication ID | 17599703 |
| P5875 | ResearchGate publication ID | 6237316 |
| P2093 | author name string | Ashish Arora | |
| Rohit Bakshi | |||
| Mohit Neema | |||
| S Scott Panter | |||
| James Stankiewicz | |||
| Courtney E Batt | |||
| P2860 | cites work | Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome | Q24562778 |
| A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome | Q28210032 | ||
| Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis | Q28290519 | ||
| Iron, brain ageing and neurodegenerative disorders | Q29615656 | ||
| MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease | Q30600007 | ||
| Magnetic resonance imaging of brain iron | Q30773535 | ||
| Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging | Q30798409 | ||
| Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name | Q30884537 | ||
| Imaging iron stores in the brain using magnetic resonance imaging | Q30983609 | ||
| Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss | Q31032545 | ||
| Magnetic resonance imaging of iron deposition in neurological disorders | Q31086982 | ||
| Superficial siderosis: a case report and review of the literature | Q31089897 | ||
| T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis | Q31108861 | ||
| Redox-active iron mediates amyloid-beta toxicity | Q31967419 | ||
| Iron metabolism in Parkinsonian syndromes | Q33248678 | ||
| Potential sources of increased iron in the substantia nigra of parkinsonian patients | Q33259219 | ||
| Glycochelates and the etiology of diabetic peripheral neuropathy | Q33864190 | ||
| In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging | Q33886369 | ||
| Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention | Q33903066 | ||
| Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. | Q34082498 | ||
| Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease | Q34083035 | ||
| The physiopathological significance of ceruloplasmin. A possible therapeutic approach. | Q34099972 | ||
| Brain iron homeostasis. | Q34173240 | ||
| Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring | Q34200598 | ||
| Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? | Q34202970 | ||
| Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial | Q34283745 | ||
| Vitamin E and donepezil for the treatment of mild cognitive impairment | Q34411313 | ||
| Use of desferrioxamine in the treatment of aceruloplasminemia | Q34419336 | ||
| Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis | Q34529405 | ||
| A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease | Q34530632 | ||
| Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity | Q34537576 | ||
| Deep grey matter "black T2" on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis | Q34624009 | ||
| Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis | Q34649942 | ||
| Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. | Q34744746 | ||
| Iron misregulation in the brain: a primary cause of neurodegenerative disorders | Q35172307 | ||
| The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy | Q35545150 | ||
| Iron and Parkinson's Disease: Chelators to the Rescue? | Q35556960 | ||
| The free radical hypothesis in idiopathic parkinsonism: evidence against it | Q35626740 | ||
| Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux | Q35632453 | ||
| Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders | Q35753865 | ||
| Iron and oxygen radicals in brain | Q35753872 | ||
| Iron metabolism and the IRE/IRP regulatory system: an update | Q35754458 | ||
| Heme oxygenase-1: transducer of pathological brain iron sequestration under oxidative stress | Q35754477 | ||
| Oxidative stress and redox-active iron in Alzheimer's disease | Q35754505 | ||
| Hereditary causes of disturbed iron homeostasis in the central nervous system | Q35754524 | ||
| Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis | Q35754529 | ||
| Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. | Q35754533 | ||
| Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. | Q36177188 | ||
| Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent | Q36349617 | ||
| Echo-spacing optimization for the simultaneous measurement of reversible (R2') and irreversible (R2) transverse relaxation rates | Q36447501 | ||
| The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging | Q36449196 | ||
| A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease | Q36618897 | ||
| Advances in the treatment of Parkinson's disease | Q36720216 | ||
| Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains | Q46915316 | ||
| Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys | Q46916058 | ||
| Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid | Q47276775 | ||
| MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease | Q47376890 | ||
| Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights | Q47813038 | ||
| Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice | Q47969552 | ||
| In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. | Q48149774 | ||
| Increased iron in the dentate nucleus of patients with Friedrich's ataxia | Q48166308 | ||
| Isoforms of ferritin have a specific cellular distribution in the brain | Q48167065 | ||
| Increased nigral iron content in postmortem parkinsonian brain | Q48182830 | ||
| T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content | Q48220896 | ||
| Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? | Q48225776 | ||
| MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects | Q48228911 | ||
| MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content | Q48235045 | ||
| Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate | Q48269852 | ||
| Inhibition of iron-dependent and ischemia-induced brain damage by the alpha-tocopherol analogue MDL 74,722. | Q48299567 | ||
| T2 relaxation time in patients with Parkinson's disease | Q48310814 | ||
| Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores | Q48311426 | ||
| Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis | Q48319417 | ||
| Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients | Q48326834 | ||
| MRI of brain iron | Q48328038 | ||
| Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE | Q48328637 | ||
| Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. | Q48346436 | ||
| Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation | Q48349192 | ||
| MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images | Q48380452 | ||
| Brain trace elements in Alzheimer's disease | Q48401098 | ||
| Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance | Q48443119 | ||
| Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis | Q48450463 | ||
| Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. | Q48453211 | ||
| Biological significance of iron-related magnetic resonance imaging changes in the brain | Q48461384 | ||
| Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability | Q48508937 | ||
| Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity | Q48524379 | ||
| Magnetic field correlation imaging | Q48539996 | ||
| Antioxidant responses of cortex neurons to iron loading. | Q48574595 | ||
| Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine | Q48590757 | ||
| Brain ferritin iron may influence age- and gender-related risks of neurodegeneration | Q48606069 | ||
| Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5 T. | Q48612954 | ||
| Iron deposits in multiple sclerosis and Alzheimer's disease brains | Q48682014 | ||
| A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study | Q48725577 | ||
| The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons | Q48753360 | ||
| MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis | Q48825761 | ||
| In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage | Q48829730 | ||
| FLAIR MRI of striatonigral degeneration | Q48887180 | ||
| Magnetic resonance imaging of corticobasal degeneration | Q48904009 | ||
| Iron deposits surrounding multiple sclerosis plaques. | Q48917061 | ||
| MR imaging of cerebral cortical involvement in aceruloplasminemia. | Q48972880 | ||
| Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate | Q49045067 | ||
| Correlation of R2 with total iron concentration in the brains of rhesus monkeys. | Q49120510 | ||
| The pathogenesis of superficial siderosis of the central nervous system. | Q50527592 | ||
| The effect of age on the non-haemin iron in the human brain. | Q51318963 | ||
| MR detection of brain iron | Q36755391 | ||
| Hereditary caeruloplasmin deficiency: clinicopathological study of a patient | Q36834658 | ||
| In vivo measurement of T2 distributions and water contents in normal human brain | Q36839935 | ||
| Theory and application of static field inhomogeneity effects in gradient-echo imaging. | Q36852458 | ||
| Oxidative stress as a cause of Parkinson's disease | Q37003217 | ||
| A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. | Q40840968 | ||
| The possible role of iron in the etiopathology of Parkinson's disease | Q40868666 | ||
| Relationship of iron to oligodendrocytes and myelination | Q41087116 | ||
| Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease | Q41117111 | ||
| Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen | Q41251425 | ||
| Oxidative stress and the pathogenesis of Parkinson's disease | Q41262986 | ||
| Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice | Q41593145 | ||
| Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents | Q41679218 | ||
| Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species | Q41959326 | ||
| Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients | Q41981840 | ||
| Decreased ferritin levels in brain in Parkinson's disease | Q42000755 | ||
| Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains | Q42477389 | ||
| Toluene abuse: physical basis for hypointensity of the basal ganglia on T2-weighted MR images | Q42493486 | ||
| Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up | Q42653222 | ||
| Evidence of H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin | Q42796062 | ||
| Palatal tremor and cognitive decline in neuroferritinopathy | Q43045073 | ||
| Effects of an extracellular metal chelator on neurovascular function in diabetic rats | Q43622537 | ||
| T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major | Q43627695 | ||
| Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis | Q43627953 | ||
| Iron chelation improves endothelial function in patients with coronary artery disease. | Q43636907 | ||
| Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. | Q43638880 | ||
| Iron on the brain | Q43692149 | ||
| Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration | Q43735211 | ||
| Dextran-coupled deferoxamine improves outcome in a murine model of head injury | Q43898793 | ||
| Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights | Q44014364 | ||
| A non-essential function for yeast frataxin in iron-sulfur cluster assembly | Q44159145 | ||
| Use of allopurinol and deferoxamine in cellular protection during ischemia | Q44205743 | ||
| Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity | Q44231054 | ||
| Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease | Q44386905 | ||
| Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis | Q44554584 | ||
| T2 values in the human brain: comparison with quantitative assays of iron and ferritin | Q44583884 | ||
| The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis | Q44695275 | ||
| Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats | Q44697081 | ||
| Nutritional iron deprivation attenuates kainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration | Q44856759 | ||
| The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice | Q45090946 | ||
| Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children | Q46557394 | ||
| Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases | Q46682421 | ||
| Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion | Q46718289 | ||
| A transient treatment of hippocampal neurons with alpha-tocopherol induces a long-lasting protection against oxidative damage via a genomic action | Q46730699 | ||
| Desmethyl tirilazad improves neurologic function after hypoxic ischemic brain injury in piglets. | Q51399003 | ||
| Deferoxamine improves spatial memory performance following experimental brain injury in rats. | Q52048500 | ||
| Intramuscular desferrioxamine in patients with Alzheimer's disease | Q52098584 | ||
| Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. | Q52371728 | ||
| Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. | Q52926826 | ||
| Transferrin C2, metal binding and Alzheimer's disease. | Q53329063 | ||
| Oxidative stress, mitochondrial respiration, and Parkinson's disease. | Q53909758 | ||
| Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. | Q55066167 | ||
| Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains | Q61714001 | ||
| Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? | Q69436285 | ||
| The relation between brain iron and NMR relaxation times: an in vitro study | Q71438088 | ||
| Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study | Q71438170 | ||
| A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators | Q71477273 | ||
| Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the anti-oxidant, butylated hydroxyanisole | Q71586083 | ||
| Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths | Q71629150 | ||
| Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions | Q71894700 | ||
| Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease | Q72319648 | ||
| Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats | Q72556738 | ||
| Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis | Q72755973 | ||
| MR evaluation of age-related increase of brain iron in young adult and older normal males | Q73184477 | ||
| Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites | Q73317141 | ||
| An MRI method for measuring T2 in the presence of static and RF magnetic field inhomogeneities | Q73403089 | ||
| The basal ganglia in haemochromatosis | Q73420750 | ||
| MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation | Q73467304 | ||
| A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis | Q73942282 | ||
| High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators | Q74646450 | ||
| T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study | Q77486197 | ||
| T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores | Q80837762 | ||
| T2rho-weighted contrast in MR images of the human brain | Q81054119 | ||
| Determination of transverse relaxation rate for estimating iron deposits in central nervous system | Q81133314 | ||
| Ceruloplasmin in neurodegenerative diseases | Q81440799 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 371-386 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Iron in chronic brain disorders: imaging and neurotherapeutic implications | |
| P478 | volume | 4 |
| Q30903353 | 3D high spectral and spatial resolution imaging of ex vivo mouse brain |
| Q42149772 | A general analysis of calibrated BOLD methodology for measuring CMRO2 responses: comparison of a new approach with existing methods |
| Q98205066 | A preliminary study of the concentration of metallic elements in the blood of patients with multiple sclerosis as measured by ICP-MS |
| Q26852354 | A review of calibrated blood oxygenation level-dependent (BOLD) methods for the measurement of task-induced changes in brain oxygen metabolism |
| Q46172327 | A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis |
| Q28830683 | Aceruloplasminemia With Psychomotor Excitement and Neurological Sign Was Improved by Minocycline (Case Report) |
| Q38238656 | Alteration of the coenzyme A biosynthetic pathway in neurodegeneration with brain iron accumulation syndromes |
| Q22251261 | Alzheimer's disease as homeostatic responses to age-related myelin breakdown |
| Q44564326 | Analysis of multiple sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI. |
| Q33726147 | Application of calibrated fMRI in Alzheimer's disease |
| Q26779470 | Appraising the Role of Iron in Brain Aging and Cognition: Promises and Limitations of MRI Methods |
| Q49113462 | Assessing global and regional iron content in deep gray matter as a function of age using susceptibility mapping |
| Q36215968 | Behavioral and Neurochemical Deficits in Aging Rats with Increased Neonatal Iron Intake: Silibinin's Neuroprotection by Maintaining Redox Balance |
| Q35998171 | Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes |
| Q45404273 | Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. |
| Q44615797 | Brain iron deposition in essential tremor: a quantitative 3-Tesla magnetic resonance imaging study. |
| Q57260042 | Brain iron levels in attention-deficit/hyperactivity disorder: A pilot MRI study |
| Q34568633 | Brain iron redistribution in mesial temporal lobe epilepsy: a susceptibility-weighted magnetic resonance imaging study |
| Q46301002 | Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis |
| Q37921764 | Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives |
| Q28580447 | Comparison of changes in gene expression of transferrin receptor-1 and other iron-regulatory proteins in rat liver and brain during acute-phase response |
| Q34116133 | Correlation of putative iron content as represented by changes in R2* and phase with age in deep gray matter of healthy adults |
| Q48386590 | Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis |
| Q37388227 | Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis |
| Q57911755 | Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis |
| Q92577571 | Dexras1 Deletion and Iron Chelation Promote Neuroprotection in Experimental Optic Neuritis |
| Q48023988 | Differential Effect of Acute Iron Overload on Oxidative Status and Antioxidant Content in Regions of Rat Brain |
| Q37423548 | Dissociation between iron accumulation and ferritin upregulation in the aged substantia nigra: attenuation by dietary restriction. |
| Q36508977 | Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity |
| Q33732997 | Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration |
| Q41189468 | Endosome-mitochondria interactions are modulated by iron release from transferrin. |
| Q28731919 | Evaluation of brain iron content based on magnetic resonance imaging (MRI): comparison among phase value, R2* and magnitude signal intensity |
| Q64081176 | Evaluation of iron deposition in brain basal ganglia of patients with Parkinson's disease using quantitative susceptibility mapping |
| Q38065116 | Excess iron harms the brain: the syndromes of neurodegeneration with brain iron accumulation (NBIA). |
| Q36374574 | First report of co-morbidity of pantothenate kinase-associated neurodegeneration and three types of chronic hemolytic anemias. |
| Q50532074 | Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. |
| Q41836301 | Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). |
| Q43288665 | Getting to the "Heart" of Cardiac Disease by Decreasing Mitochondrial Iron. |
| Q57898104 | Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders? |
| Q35243782 | Human brain iron mapping using atlas-based T2 relaxometry |
| Q40971704 | Imaging and quantification of iron-oxide nanoparticles (IONP) using MP-RAGE and UTE based sequences |
| Q33623847 | In vivo structural imaging of the cerebellum, the contribution of ultra-high fields |
| Q34543407 | Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease |
| Q48302457 | Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome |
| Q34798799 | Inhibition of Sirtuin 2 exerts neuroprotection in aging rats with increased neonatal iron intake |
| Q31152127 | Inversion recovery ultrashort echo time magnetic resonance imaging: A method for simultaneous direct detection of myelin and high signal demonstration of iron deposition in the brain - A feasibility study |
| Q44443968 | Involvement of globus pallidus and midbrain nuclei in pantothenate kinase-associated neurodegeneration: measurement of T2 and T2* time |
| Q35379973 | Iron and neurodegeneration in multiple sclerosis |
| Q28388335 | Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases |
| Q31020168 | Iron deposition and inflammation in multiple sclerosis. Which one comes first? |
| Q48619811 | Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study |
| Q48591960 | Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy |
| Q26829932 | Iron dysregulation in Huntington's disease |
| Q26771174 | Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping |
| Q36915757 | Iron regulatory proteins increase neuronal vulnerability to hydrogen peroxide |
| Q39752057 | Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial |
| Q34801617 | Kinetics of iron import into developing mouse organs determined by a pup-swapping method |
| Q58587214 | Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder |
| Q38064534 | Limbic system pathologies associated with deficiencies and excesses of the trace elements iron, zinc, copper, and selenium. |
| Q38766599 | Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry |
| Q33941442 | MRI assessment of iron deposition in multiple sclerosis |
| Q39722043 | MRI findings in neuroferritinopathy |
| Q33345057 | MRI in multiple sclerosis: current status and future prospects |
| Q31132442 | MRI in multiple sclerosis: what's inside the toolbox? |
| Q57094839 | MRI-Based Quantification of Magnetic Susceptibility in Gel Phantoms: Assessment of Measurement and Calculation Accuracy |
| Q89938771 | Magnetic Resonance Imaging in Multiple Sclerosis |
| Q27325407 | Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's disease |
| Q36864333 | Magnetic resonance imaging of myelin |
| Q38109630 | Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures |
| Q34073566 | Metal imaging in neurodegenerative diseases |
| Q48116952 | Metals and electrolytes in sclerotic hippocampi in patients with drug-resistant mesial temporal lobe epilepsy |
| Q34269043 | Midlife migraine and late-life parkinsonism: AGES-Reykjavik study |
| Q50669013 | Missense PANK2 mutation without "eye of the tiger" sign: MR findings in a large group of patients with pantothenate kinase-associated neurodegeneration (PKAN). |
| Q55383406 | Multi-parametric quantitative MRI reveals three different white matter subtypes. |
| Q57911763 | Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: The Neuroimaging Perspective |
| Q27023735 | Multiple sclerosis: molecular mechanisms and therapeutic opportunities |
| Q47098715 | Neurochemical and Behavior Deficits in Rats with Iron and Rotenone Co-treatment: Role of Redox Imbalance and Neuroprotection by Biochanin A. |
| Q35975904 | Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy |
| Q61051564 | Neuroimaging in dementia |
| Q31166509 | New rapid, accurate T2 quantification detects pathology in normal-appearing brain regions of relapsing-remitting MS patients. |
| Q57186503 | Non-Carcinogenic Risk Assessment of Heavy Metals and Fluoride in Some Water Wells in the Al-Baha Region, Saudi Arabia |
| Q41988403 | On the role of physiological fluctuations in quantitative gradient echo MRI: implications for GEPCI, QSM, and SWI. |
| Q38124286 | Pathophysiology and treatment of neurodegeneration with brain iron accumulation in the pediatric population |
| Q34375802 | Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis |
| Q40974003 | Potassium as a pluripotency-associated element identified through inorganic element profiling in human pluripotent stem cells |
| Q47093884 | Quantitative Susceptibility Mapping Reveals an Association between Brain Iron Load and Depression Severity |
| Q36526057 | Quantitative Susceptibility Mapping: Contrast Mechanisms and Clinical Applications. |
| Q48553203 | Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis |
| Q50999549 | Quantitative assessment of brain iron by R2* relaxometry in patients with cervical dystonia. |
| Q48568405 | Quantitative measurement of brain iron deposition in patients with haemodialysis using susceptibility mapping |
| Q47906957 | Real-time Correction of Motion and Imager Instability Artifacts during 3D γ-Aminobutyric Acid-edited MR Spectroscopic Imaging |
| Q52678256 | Redox metals homeostasis in multiple sclerosis and amyotrophic lateral sclerosis: a review. |
| Q47242221 | Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis |
| Q33757630 | Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis |
| Q34303664 | Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration |
| Q42448140 | Signal changes in cortical laminar necrosis-evidence from susceptibility-weighted magnetic resonance imaging |
| Q51672185 | Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study. |
| Q48553659 | Sub-lethal levels of amyloid β-peptide oligomers decrease non-transferrin-bound iron uptake and do not potentiate iron toxicity in primary hippocampal neurons. |
| Q48108134 | Surgical trauma induces iron accumulation and oxidative stress in a rodent model of postoperative cognitive dysfunction |
| Q37949887 | Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations |
| Q42454590 | T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis |
| Q42454595 | T2' imaging indicates decreased tissue metabolism in frontal white matter of MS patients. |
| Q41769794 | Thalamic paramagnetic iron by T2* relaxometry correlates with severity of multiple sclerosis |
| Q37459099 | The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis |
| Q99616848 | The S-nitrosylation of parkin attenuated the ubiquitination of divalent metal transporter 1 in MPP+-treated SH-SY5Y cells |
| Q24289511 | Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples |
| Q37772026 | Translational research in neurology and neuroscience 2010: multiple sclerosis |
| Q46205383 | Ultra-short echo time images quantify high liver iron |
| Q34193600 | Vascular aspects of multiple sclerosis. |
| Q48707884 | White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. |
| Q26778937 | Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease |
Search more.